Literature DB >> 23362291

Congenital toxoplasma infection: monthly prenatal screening decreases transmission rate and improves clinical outcome at age 3 years.

M Wallon1, F Peyron, C Cornu, S Vinault, M Abrahamowicz, C Bonithon Kopp, C Binquet.   

Abstract

BACKGROUND: Toxoplasma infection during pregnancy exposes the fetus to risks of congenital infection and sequelae that depend heavily on gestational age (GA) at time of infection. Accurate risk estimates by GA are necessary to counsel parents and improve clinical decisions.
METHODS: We analyzed data from pregnant women diagnosed with acute Toxoplasma infection in Lyon (France) from 1987 to 2008 and assessed how the risks of congenital toxoplasmosis and of clinical signs at age 3 years vary depending on GA at the time of maternal infection.
RESULTS: Among 2048 mother-infant pairs, 93.2% of mothers received prenatal treatment and 513 (24.7%) fetuses were infected. Because of a significant reduction in risk since 1992 when monthly screening was introduced (59.4% vs 46.6% at 26 GA weeks; P = .038), probabilities of infection were estimated on the basis of maternal infections diagnosed after mid-1992 (n = 1624). Probabilities of congenital infection were <10% for maternal infections before 12 weeks of gestation, rose to 20.0% at 19 weeks, and then continued increasing to 52.3% and almost 70% at 28 and 39 GA weeks, respectively. Because of a significant reduction in risk of clinical signs of congenital toxoplasmosis in infected children born from mothers diagnosed after 1995 when polymerase chain reaction testing on amniotic fluid was initiated (87/794 vs 46/1150; P = .012), probabilities of clinical signs at 3 years were estimated based on 1015 maternal infections diagnosed after 1995 including 207 infected children, with symptoms in 46 (22.2%).
CONCLUSIONS: These analyses demonstrated that introduction of monthly prenatal screening and improvement in antenatal diagnosis were associated with a significant reduction in the rate of congenital infection and a better outcome at 3 years of age in infected children. Our updated estimates will improve individual management and counseling in areas where genotype II Toxoplasma is predominant.

Entities:  

Mesh:

Year:  2013        PMID: 23362291     DOI: 10.1093/cid/cit032

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  56 in total

1.  Reply to Wallon and Peyron.

Authors:  Rima McLeod; Kelsey M Wheeler; Kenneth Boyer
Journal:  Clin Infect Dis       Date:  2015-12-21       Impact factor: 9.079

2.  Understanding Toxoplasmosis in the United States Through "Large Data" Analyses.

Authors:  Joseph Lykins; Kanix Wang; Kelsey Wheeler; Fatima Clouser; Ashtyn Dixon; Kamal El Bissati; Ying Zhou; Christopher Lyttle; Andrey Rzhetsky; Rima McLeod
Journal:  Clin Infect Dis       Date:  2016-06-26       Impact factor: 9.079

3.  Toxoplasma genotyping in congenital toxoplasmosis in Upper Egypt: evidence of type I strain.

Authors:  Hanan E M Eldeek; Alzahraa Abdel Raouf Ahmad; Mohamed Ahmed El-Mokhtar; Abdel Rahman M M Abdel Kader; Ahmad M Mandour; Mahmoud Elhady M Mounib
Journal:  Parasitol Res       Date:  2017-07-01       Impact factor: 2.289

4.  Induction of specific humoral immune response in mice immunized with ROP18 nanospheres from Toxoplasma gondii.

Authors:  Habibun Nabi; Imran Rashid; Nisar Ahmad; Aneela Durrani; Haroon Akbar; Saher Islam; Amna Arshad Bajwa; Wasim Shehzad; Kamran Ashraf; Nyla Imran
Journal:  Parasitol Res       Date:  2016-10-27       Impact factor: 2.289

5.  Evaluation of Toxoplasma ELITe MGB Real-Time PCR Assay for Diagnosis of Toxoplasmosis.

Authors:  Florence Robert-Gangneux; Marie-Pierre Brenier-Pinchart; Hélène Yera; Sorya Belaz; Emmanuelle Varlet-Marie; Patrick Bastien
Journal:  J Clin Microbiol       Date:  2017-02-15       Impact factor: 5.948

6.  Plasmonic gold chips for the diagnosis of Toxoplasma gondii, CMV, and rubella infections using saliva with serum detection precision.

Authors:  Xiaoyang Li; Christelle Pomares; François Peyron; Cynthia J Press; Raymund Ramirez; Gonfrier Geraldine; Isabelle Cannavo; Emmanuelle Chapey; Pauline Levigne; Martine Wallon; Jose G Montoya; Hongjie Dai
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2019-01-30       Impact factor: 3.267

7.  Maternal Anti-Toxoplasma Treatment during Pregnancy Is Associated with Reduced Sensitivity of Diagnostic Tests for Congenital Infection in the Neonate.

Authors:  Hélène Guegan; Tijana Stajner; Branko Bobic; Cindy Press; Rares T Olariu; Kjerstie Olson; Jelena Srbljanovic; Jose G Montoya; Olgica Djurković-Djaković; Florence Robert-Gangneux
Journal:  J Clin Microbiol       Date:  2021-01-21       Impact factor: 5.948

8.  Clustering of Toxoplasma gondii Infections Within Families of Congenitally Infected Infants.

Authors:  Despina Contopoulos-Ioannidis; Kelsey M Wheeler; Raymund Ramirez; Cindy Press; Ernest Mui; Ying Zhou; Christine Van Tubbergen; Sheela Prasad; Yvonne Maldonado; Shawn Withers; Kenneth M Boyer; A Gwendolyn Noble; Peter Rabiah; Charles N Swisher; Peter Heydemann; Kristen Wroblewski; Theodore Karrison; Michael E Grigg; Jose G Montoya; Rima McLeod
Journal:  Clin Infect Dis       Date:  2015-09-24       Impact factor: 9.079

9.  Toxoplasmosis among pregnant women: high seroprevalence and risk factors in Kinshasa, Democratic Republic of Congo.

Authors:  Yobi Doudou; Piarroux Renaud; L'Ollivier Coralie; Franck Jacqueline; Situakibanza Hypolite; Muhindo Hypolite; Mitashi Patrick; Inocêncio da Luz Raquel Andreia; Marc Van Sprundel; Boelaert Marleen; Jean-Pierre Van Geertruyden; Lutumba Pascal
Journal:  Asian Pac J Trop Biomed       Date:  2014-01

Review 10.  Treatment of Toxoplasmosis: Historical Perspective, Animal Models, and Current Clinical Practice.

Authors:  Ildiko Rita Dunay; Kiran Gajurel; Reshika Dhakal; Oliver Liesenfeld; Jose G Montoya
Journal:  Clin Microbiol Rev       Date:  2018-09-12       Impact factor: 26.132

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.